The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of...

Descripción completa

Detalles Bibliográficos
Autores: Bonanno, Laura|||0000-0001-5218-4970, Costa, Carlota, Majem Tarruella, Margarita|||0000-0002-9919-7485, Sanchez, José Javier, Giménez-Capitán, Ana|||0000-0003-2575-1225, Rodriguez, Ignacio, Vergnenegre, Alain, Massuti, Bartomeu|||0000-0002-6247-4493, Favaretto, Adolfo, Rugge, Massimo, Pallares, Cinta, Taron, Miquel, Rosell, Rafael|||0000-0003-0817-3400
Tipo de recurso: artículo
Fecha de publicación:2013
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303829
Acceso en línea:https://ddd.uab.cat/record/303829
https://dx.doi.org/urn:doi:10.18632/oncotarget.1157
Access Level:acceso abierto
Palabra clave:53BP1
BRCA1
DNA repair
Platinum
Predictive modeling
Descripción
Sumario:Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P <0.0001) and overall survival was 8.2 months (P=0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy.

Similares en LA Referencia